ArticleBiomolecules2025
Cold Atmospheric Plasma Enhances TGF-β1, CTGF Protein Expression, and Healing in Full-Thickness Skin Burns: An Animal Study.
Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cold atmospheric plasma (CAP) interacts with tissues, leading to fast wound disinfection. Given the frequent global burden of burn injuries and the risks of infection associated with acute full-thickness burns (FTBs), this investigation examined CAP as a potential therapeutic method for wound healing due to its antimicrobial and pro-healing effects. Here, we examined the impacts of CAP on the healing of wounds resulting from acute FTSBs. We established an animal model that included four groups: (1) healthy control animals without burns, (2) untreated animals with acute FTSBs, (3) animals with acute FTSBs treated with CAP for 5 s per day for 21 days, and (4) animals with acute FTSBs treated with CAP for 10 s per day for 21 days. Wound healing was assessed using immunohistological methods. In animals with FTSBs, CAP therapy was accompanied by (i) accelerated wound closure, (ii) enhanced regeneration of the dermis and epidermis, and (iii) increased protein expression of transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF). These changes were more pronounced following CAP treatment for 10 s per day compared to CAP treatment for 5 s per day.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.